Your SlideShare is downloading. ×
  • Like

Thanks for flagging this SlideShare!

Oops! An error has occurred.


Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Addressing The Challenge Of Patient Non Complaince


Addressing the Challenge of Patient Non-Compliance - Separating the Non-Compliers from the Non-Responders.

Addressing the Challenge of Patient Non-Compliance - Separating the Non-Compliers from the Non-Responders.

Published in Health & Medicine , Business
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads


Total Views
On SlideShare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. Addressing the Challenge of Patient Non-Compliance Non- Separating the Non-Compliers from the Non-Responders Non- Non-
  • 2. Today’s Topic: Patient Non-Compliance • Discover the population profiles for non-compliance • Reveal the underlying reasons – symptomatic versus asymptomatic patients • The implications of non-compliance p p • Strategies for reducing non-compliance risk • What is the value for addressing this issue? • What are the industry obligations we face moving forward?
  • 3. What Do We Mean by Non-Compliance? Non-compliance is the degree to which behavior fails to coincide with medical recommendations in …taking medication, attending clinical appointments, following exercise or diet regimens and engaging in preventative behavior* *Haynes RB Taylor DW, Sackett DL (eds) Compliance in Health Care Haynes RB, DW (eds).
  • 4. There is No Excuse for Ignorance • “Keep watch also on the fault of patients which makes them lie about taking f thi t ki of things prescribed” ib d” Hippocrates, circa 500 BC • “Drugs don’t work if people don’t take them” C. Everett Koop, 1985 • I Ignoring th well-know i i the ll k issue of patient non-compliance or non- f ti t li adherence makes no sense, especially when it is simple to turn a liability into an asset • Estimated annual cost to the US Health Care System of non- compliance with prescribed medication over $175B • Ernst & Grizzle, JAPharmA, 2001 • 50 percent of patients are non-compliant • Boddenheimer & Fernandez, Ann Int Med, 2005 , ,
  • 5. Non-Compliance in the Clinical Trial Setting • Results of non-compliance include: – Loss of subjects to follow up – Loss of patients to side effects – S bj t not meeting clinical criteria t Subjects t ti li i l it i to continue in the study – Injection of error variance into the study – Failure to complete the study with enough participants to produce statistically significant results – Requirement to increase sample sizes to compensate for error variance p
  • 6. How do you Ensure Non-Adherence is not Undermining your Data? • Traditional approaches to addressing non- compliance – Patient self reports – Medication diaries – Tablet counts – Monitoring plasma levels • Electronic compliance data show that many of these traditional practices are ineffective • Parking Lot Syndrome • Weekend/Holiday
  • 7. Why Non-Compliance?? • Lack of symptoms y p • Side effects • Unable to understand dosing instructions g – Complicated – Language/Translation issues • Forgetfulness – Generally accepted that blister cards provide a better opportunity for adherence – Calendar packs • Complicated multiple drug regimens
  • 8. Electronic Compliance Monitors Pros Cons • Smaller sample sizes or • Increased cost • Increased statistical power • Increased complexity – Greater confidence – Time • Quicker decision making • User acceptance • Quicker regulatory approval – What to do with the data • More accurate dosing information • Intra trial feedback • Positive ROI
  • 9. Mandating Electronic Compliance Monitoring • Will the FDA issue a mandate as these devices become cost effective and reliable? • Case Study: NIH sponsored a trial – Regimen of 1x day for one year – COPD population – Made the assumption that this type of trial would typically be plagued with non-compliance
  • 10. Adherence Data Can Increase Statistical Power • Resulting in positive ROI • Reliability is no longer an issue • Stricter co p a ce requirements may actua y St cte compliance equ e e ts ay actually reduce the N for a trial • Sample training • Intra-trial feedback • Adjusting trial data post hoc for non compliance • Better correlation of drug/Adverse Events • More accurate dosing information
  • 11. Sample Scenarios • Opiate analgesics – Reduce dependence liability p y – Reduce medico-legal liability – Increase clinical effectiveness • PRN medications; migraine medications medications, sleep medication • Critical window drugs – Combination therapies, e.g. HIV, chemotherapies – High toxicity drugs • Mandated pharmacotherapy, e.g. cyproterone, naltrexone, INH • Combination therapies, e.g. HIV, chemotherapies – High toxicity drugs
  • 12. Special Populations • Geriatric populations • Psychiatric populations • Addicted populations • Third-world populations • Poorly motivated populations – Where non adherence causes no symptoms non-adherence – Where non-adherence is catastrophic • Chronic indications where patients must take medication for long periods of time, e.g. diabetes, organ rejection
  • 13. Technology to Address Non-Compliance • Current and planned generations of electronic compliance monitors fit increasingly seamlessly into the trials process – High reliability – Patient friendly – no patient input required – User friendly – Highly flexible according to fit user requirements
  • 14. Three Practical Recommendations for Sponsors Today • When considering electronic compliance, early involvement from the technical team is critical • Have a strategy for using the data • Old paradigms no longer apply